- Home
- MEDP vs RPRX Comparison
MEDP vs RPRX Comparison
Compare MEDP & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MEDP
- RPRX
- Stock Information
- Founded
- MEDP 1992
- RPRX 1996
- Country
- MEDP United States
- RPRX United States
- Employees
- MEDP N/A
- RPRX N/A
- Industry
- MEDP Biotechnology: Commercial Physical & Biological Resarch
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- MEDP Health Care
- RPRX Health Care
- Exchange
- MEDP Nasdaq
- RPRX Nasdaq
- Market Cap
- MEDP 10.5B
- RPRX 11.7B
- IPO Year
- MEDP 2016
- RPRX 2020
- Fundamental
- Price
- MEDP $341.65
- RPRX $25.40
- Analyst Decision
- MEDP Buy
- RPRX Strong Buy
- Analyst Count
- MEDP 10
- RPRX 6
- Target Price
- MEDP $389.00
- RPRX $41.67
- AVG Volume (30 Days)
- MEDP 257.2K
- RPRX 3.2M
- Earning Date
- MEDP 02-10-2025
- RPRX 02-13-2025
- Dividend Yield
- MEDP N/A
- RPRX 3.33%
- EPS Growth
- MEDP 33.84
- RPRX 518.56
- EPS
- MEDP 11.42
- RPRX 2.55
- Revenue
- MEDP $2,070,866,000.00
- RPRX $2,266,003,000.00
- Revenue This Year
- MEDP $13.95
- RPRX $12.21
- Revenue Next Year
- MEDP $5.82
- RPRX $11.13
- P/E Ratio
- MEDP $30.00
- RPRX $9.88
- Revenue Growth
- MEDP 16.24
- RPRX N/A
- 52 Week Low
- MEDP $277.72
- RPRX $24.05
- 52 Week High
- MEDP $459.77
- RPRX $31.66
- Technical
- Relative Strength Index (RSI)
- MEDP 50.57
- RPRX 44.79
- Support Level
- MEDP $326.92
- RPRX $24.05
- Resistance Level
- MEDP $342.73
- RPRX $25.35
- Average True Range (ATR)
- MEDP 10.02
- RPRX 0.53
- MACD
- MEDP -0.51
- RPRX 0.03
- Stochastic Oscillator
- MEDP 45.26
- RPRX 48.62
About MEDP Medpace Holdings Inc.
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical-device firms. It also offers ancillary services such as bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has over 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati and its operations are principally based in the us, but it also operates in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.